Briefly, we have argued that use of methylene blue as a non-physiological reductant obscures the core challenge of how to interpret the ability of 1MT racemers to inhibit IDO2 activity in cells where it may make relevant contributions to normal physiology or pathophysiology, for example, in cancer or autoimmunity. The gene discussed is IDO2; the disease is cancer.